Regulatory changes
Can delay product approvals
- Materiality
- high
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases. The company focuses on providing innovative medicines in haematology, immunology, and specialty care. With approximately 1,800 employees, Sobi operates across Europe, North America, the Middle East, Asia, and Australia. In 2024, Sobi reported a revenue of SEK 26 billion and is publicly traded on Nasdaq Stockholm under the ticker STO:SOBI.
1.9k
0.90
0.56
| % | |
|---|---|
| Haematology | 63% Includes treatments for haemophilia and related conditions |
| Immunology | 32% Comprises medicines for immune system disorders |
| Specialty Care | 5% Focuses on rare diseases and niche therapeutic areas |
Sobi serves a diverse range of customers, primarily focusing on healthcare providers and institutions that treat rare...
- Healthcare Providersprimary
Hospitals and clinics purchasing treatments for rare diseases
- Specialized Clinicssecondary
Focused on haemophilia and immunology treatments
- Emerging Marketsemerging
Growing demand for innovative therapies
Sobi operates globally, with a strong presence in Europe, North America, and expanding markets in the Middle East,...
- •Headquartered in Stockholm, Sweden
- •Strong presence in Europe and North America
- •Expanding into Asia and the Middle East
- •Operations in over 30 countries
- •Strategic focus on market share growth in key regions
Sobi's strategic priorities include expanding its portfolio of innovative therapies and increasing its market presence...
01
Expand innovative therapiesmedium-term
To address unmet medical needs
02
Strengthen haemophilia leadershipshort-term
To capture market share
03
Enhance R&D capabilitieslong-term
To accelerate new treatment development
Sobi faces several risks, including regulatory changes, competitive pressures, and the inherent uncertainties of drug...
Geopolitical risks
Impacts supply chains and market access
- Scope
- China
- Materiality
- high
Competitive pressures
Affects market share and pricing
- Materiality
- high
Revenue recognition timing
high
Milestone payments
medium
SEB
SEB-A.ST · Financials
Saab AB is a Swedish high-technology company specializing in defense, aviation, and civil security.
Apellis Pharmaceuticals, Inc.
Pharmaceutical Preparations
Apellis Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company built around complement inhibition, with pegcetacoplan as its core molecule.
Oncopeptides
ONCO.ST · Health Care
Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases.
BioInvent International
BINV.ST · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
Fulcrum Therapeutics, Inc.
FULC · Pharmaceutical Preparations
ANI PHARMACEUTICALS INC
ANIP · Pharmaceutical Preparations
ANI Pharmaceuticals is a U.S.-based biopharmaceutical company that develops, manufactures, and commercializes prescription therapeutics across Rare Disease, Generics, and Brands.
: 11/08/2026